吉非替尼挽救性治疗晚期非小细胞肺癌的初步观察

为了观察吉非替尼（gefitinih）挽救性治疗化疗失败的晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的疗效和不良反应，给45例化疗失败的晚期NSCLC患者口服吉非替尼250mg／d，直至病情进展或不能耐受毒性（至少30d）。结果 全组总有效率为51．1％（23／45），其中CR3例，PR20例，SD5例，疾病控制率为62．2％（28／45）。中位生存时间为4个月，其中有效者为7个月，无效者则为2个月．1年生存率为21．3％。不良反应主要为Ⅰ～Ⅱ度皮疹（64．4％）、腹泻（31．1％）和恶心呕吐（24．4％）。初步研究结果提示，吉非替尼治疗化疗失败的晚期NSCLC的疗效好，不良反应轻，有望成为晚期NSCLC一线或二线治疗标准。

Preliminary observation of gefitinib in salvage treatment of patients with previouslytreated, advanced non-small cell lung cancer

The objective of this study was to observe the effect and toxicity of gefitinib in salvage treatment of patients with previously treated, advanced non-small cell lung cancer (NSCLC). Forty-five patients received gefitinib at 250 mg/day until the disease progression or untolerable toxicity developing. The response rate, including complete and partial response, was 51.1%(23/45), and an additional 11.1% of patients achieved stable disease for an overall disease control of 62.2%(28/45). Median survival for all patients was 4 months while it reached 7 months for patients with disease control. The 1-year survival rate was 21.3% for all patients. Grade 1/2 skin rash, diarrhea and nausea were observed in 64.4%, 31.1%and 24.4% of patients, respectively. In concolusion, gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens.